Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**FullerLife C60** is a branded **dietary supplement and nutraceutical product** marketed by **Bioactive C60** and **FullerLifeC60** rather than an FDA-approved pharmaceutical. Its active ingredient is **carbon 60**, a small carbon allotrope composed of 60 carbon atoms in a spherical fullerene structure. The product has been promoted in **sublingual dissolvable strip** form using highly purified, solubilized C60 and is marketed for general wellness claims such as antioxidant support, immune support, and inflammation-related benefits. Mechanistically, C60 is generally described as a **non-specific free radical scavenger antioxidant** rather than a ligand with a defined pharmacologic receptor target. Based on the provided context, the product has **not been approved by the FDA as a drug or dietary supplement**, and the FDA issued a warning letter in 2020 over marketing FullerLife C60 with unapproved disease-related claims including COVID-19-related claims.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FullerLife C60.